Results 191 to 200 of about 15,923 (217)
Some of the next articles are maybe not open access.
Anti-TNFs in axial spondyloarthritis
Wiener Medizinische Wochenschrift, 2015Since there is no evidence regarding the efficacy of conventional synthetic disease modifying anti-rheumatic drugs in the improvement of axial spondyloarthritis (SpA), anti-tumor necrosis factors (anti-TNFs) are recommended if nonsteroidal anti-inflammatory drugs fail, or in case of high disease activity.
Roland, Kocijan +2 more
openaire +2 more sources
The Future of Imaging in Axial Spondyloarthritis
Rheumatic Disease Clinics of North America, 2020This article discusses the current position of conventional radiography and MRI, the techniques recommended by the European League Against Rheumatism for use in imaging in axial spondyloarthritis (axSpA). Several challenges and areas of development regarding radiography and MRI in axSpA are considered.
openaire +2 more sources
Golimumab for the treatment of axial spondyloarthritis
Expert Opinion on Biological Therapy, 2016Anti-TNF drugs have represented an epochal revolution in the treatment of rheumatoid arthritis and spondyloarthritis. In the field of axial spondyloarthritis, golimumab, a fully human monoclonal anti-TNFα administered subcutaneously every 4 weeks, has shown significant efficacy and good safety in patients with ankylosing spondylitis.
Carlo, Palazzi +5 more
openaire +2 more sources
Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
Therapeutic Advances in Musculoskeletal Disease, 2021J Braun +2 more
exaly
T cells in the pathogenesis of axial spondyloarthritis
Joint Bone Spine, 2023Nicolas Rosine +2 more
exaly